This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Short Term Growth in Children With Atopic Dermatitis

This study has been completed.
Information provided by:
Children´s Clinic, Randers Identifier:
First received: October 7, 2005
Last updated: December 8, 2005
Last verified: March 2005
Main objective:to assess short term growth in children with atopic dermatitis during treatment with tacrolimus 0.1% and mometasone furoate 0.1%. A singl blind randomised cross over trial including 20 children. The study consists of 5 periods: run in, treatment(1),wash out, treatment(2) and run out. Each period 14 days where the children will use tacrolimus ointment tvice daily, mometasone furoate once daily or moisturizer (in run in wash out and run out)

Condition Intervention Phase
Atopic Dermatitis Drug: tacrolimus ointment 0.1% Drug: mometasone furoate 0.1% Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single

Resource links provided by NLM:

Further study details as provided by Children´s Clinic, Randers:

Primary Outcome Measures:
  • short term growth during treatment compared to run in

Secondary Outcome Measures:
  • U-EPX
  • U-nTX
  • skin prick test

Estimated Enrollment: 20
Study Start Date: February 2005
Estimated Study Completion Date: June 2005

Ages Eligible for Study:   5 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: age 5-14, atopic dermatitis, normal current growth, Tanner 1, informed consent by the parent or guardian, willing and able to comply with study procedures

Exclusion Criteria: Tanner 2-5, treatment of atopic dermatitis with anti-inflammatory agent within 1 week before the first visit, current asthma or rhinoconjunctivitis that requires treatment with glucocorticoids, endocrine diseases, major surgery within 4 weeks prior to visit 1, fever >39.5 for >3 days

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00236106

Sponsors and Collaborators
Children´s Clinic, Randers
Principal Investigator: Ole Wolthers Children's Clinic Randers
  More Information Identifier: NCT00236106     History of Changes
Other Study ID Numbers: BKR-AD-04
Study First Received: October 7, 2005
Last Updated: December 8, 2005

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Mometasone Furoate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents processed this record on August 18, 2017